This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x
Survey about achondroplasia
We have designed a questionnaire with the purpose to better know the population connected to achondroplasia.
The questionnaire is optional and anonymous. The data obtained will be used for statistical purposes and to better understand the natural history of achondroplasia. Please consider answering.
If you would like to take the survey later, you can click on the link at the top "Register at BA"
Go to the survey Not now No, thanks

Quick BMN-111 update


BioMarin lauched on 30th April 2015 the latest investors report.

An article from Benzinga.com said: "In the report, Cowen and Company noted, "BMN-111's Phase II proof-of-concept study in achondroplasia is on track to produce data from first three dosing cohorts in June. BioMarin is optimistic that '111 can induce a 50% increase in growth velocity, and/or improve trunk and extremities proportionality.  As achondroplasia could be a $2 billion dollars plus opportunity, we think good data would be a catalyst for shares".


Lets wait for the phase II partial report in June.

To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.

Thank You.